CP, November 2018, Vol 10, No 11

Semaglutide reduces cardiovascular risk across risk subgroups

GLP-1 agonist semaglutide significantly decreases risk of cardiovascular events and death across different risk groups of patients with type 2 diabetes, secondary analysis of clinical trial data has found.…

Lifestyle interventions reduce need for antihypertensive medication in overweight people

Researchers found that assigning overweight patients to the DASH diet and a behavioural weight management programme cut the number of patients eligible for antihypertensive medication…

Study results do not support widespread use of statins in old and very old populations

Statins do not prevent the development of atherosclerotic cardiovascular disease (CVD) in people without diabetes aged 75 years and over, according to a study published in the BMJ.…